Clinical trials: Lung
Idiopathic Pulmonary Fibrosis
(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
The ARTEMIS-IPF study was conducted to determine if ambrisentan was effective in delaying disease progression and death in participants with idiopathic pulmonary fibrosis (IPF), to evaluate its safety, and to evaluate its effect…
- Trial name
- ARTEMIS-IPF (NCT00768300)
- Testing
- Ambrisentan
- Where
- 185 sites in United States, Argentina and 20 more
- Volunteers
- 494 people
- Sponsor
- Gilead Sciences
Hantavirus Pulmonary Infection, Immunisation
Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device
This is a Phase 1, randomized, placebo controlled, double-blind, dose escalation trial of 48 males and non-pregnant females, 18-49 years old, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03682107
- Testing
- Andes virus DNA vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lung Cancer
Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiosurgery in treating…
- Trial name
- NCT00852644
- Testing
- computed tomography, fludeoxyglucose F 18, hypofractionated radiation therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Boston Medical Center
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks
The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticanse propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide (125mcg) once-daily to…
- Trial name
- NCT01772134
- Testing
- Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg
- Where
- 73 sites in United States, Canada and 2 more
- Volunteers
- 617 people
- Sponsor
- GlaxoSmithKline
Dermatitis, Atopic
Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)
The Early Prevention of Asthma in Atopic Children (EPAAC™). 24 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in 12 to 24 months old children.
- Trial name
- NCT00152464
- Testing
- Levocetirizine
- Volunteers
- 514 people
- Sponsor
- UCB Pharma SA
Bacterial Infection
Safety of Intravenous Apramycin in Adults
A Phase I, open label study of a single dose of 30 mg/kg of apramycin administered intravenously (IV) over 30 (+/- 5) minutes. Twenty subjects will be enrolled in the study to one of 5 cohorts, T1-T5, each corresponding to a…
- Trial name
- NCT05590728
- Testing
- Apramycin (EBL-1003)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Arterial Hypertension
Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants
The purpose of this study was to measure the long-term safety and efficacy profile of LTP001 in participants with pulmonary arterial hypertension (PAH).
- Trial name
- NCT05764265
- Testing
- LTP001
- Where
- 12 sites in United States, Argentina and 5 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
This is a 52-week treatment, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of once-daily QVA149 (indacaterol and NVA237 ([glycopyrronium bromide]) using tiotropium as…
- Trial name
- NCT01285492
- Testing
- QVA149, Tiotropium
- Where
- 35 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD
The purpose of this 24 week study is to evaluate the spirometric lung function effect (trough FEV1) of Umeclidinium/Vilanterol 62.5/25 once daily compared to Tiotropium 18 mcg once daily along with safety assessments in subjects…
- Trial name
- NCT01777334
- Testing
- Umeclidinium/Vilanterol 62.5/25 mcg, Tiotropium 18 mcg
- Where
- 70 sites in United States, Argentina and 7 more
- Volunteers
- 905 people
- Sponsor
- GlaxoSmithKline
Pneumonia
A Study of a Vaccine for Pneumonia in Adults and Toddlers in Kenya
This study aimed to determine whether PATH-wSP, a vaccine against a germ that causes pneumonia, is safe and induces immune responses in adults and toddlers. The study vaccine was compared to placebo.
- Trial name
- NCT02543892
- Testing
- PATH-wSP
- Where
- Kenya
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- PATH
Lung Cancer
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
This research study is studying a drug intervention as a possible treatment for lung cancer. The drugs involved in this study are: Nivolumab Carboplatin Pemetrexed Ipilimumab
- Trial name
- NCT03256136
- Testing
- Carboplatin, Nivolumab, pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis
Some cystic fibrosis patients are unable to digest food and absorb nutrition appropriately as they have a condition known as exocrine pancreatic insufficiency (EPI).
- Trial name
- SPAN (NCT05719311)
- Testing
- adrulipase
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Entero Therapeutics
Pulmonary Disease, Chronic Obstructive
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444.
- Trial name
- COPD (NCT01328444)
- Testing
- GSK 573719 +GW642444 125/25, GSK573719 + GW642444 62.5/25, GSK 573719 125
- Where
- 31 sites in United States, Bulgaria and 4 more
- Volunteers
- 349 people
- Sponsor
- GlaxoSmithKline
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
PR3-AAV Resilient Remission or PRRR
The purpose of this study is to evaluate the efficacy and safety of obinutuzumab for the treatment of proteinase 3 Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (PR3-AAV).
- Conditions
- Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis
- Trial name
- NCT05376319
- Testing
- Obinutuzumab, Rituximab
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Lung Cancer
Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy
The goal of this clinical research study is to evaluate the outcome of a standard radiation treatment called stereotactic radiotherapy (SRT) for NSCLC.
- Trial name
- NCT02357992
- Testing
- Stereotactic Body Radiotherapy (SABR)
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- M.D. Anderson Cancer Center
Alpha 1-Antitrypsin Deficiency
Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, Fazirsiran Injection, administered subcutaneously to participants with alpha-1 antitrypsin…
- Trial name
- SEQUOIA (NCT03945292)
- Testing
- Fazisiran Injection
- Where
- 21 sites in United States, Germany and 4 more
- Volunteers
- 40 people
- Sponsor
- Arrowhead Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients
This is a multi-centre, randomised, double-blinded, active-controlled, 2-way cross over trial to assess the effects of once daily administration of orally inhaled tiotropium + olodaterol FDC or tiotropium (both delivered by the…
- Trial name
- NCT02629965
- Testing
- tiotropium, olodaterol
- Where
- 43 sites in Japan
- Volunteers
- 184 people
- Sponsor
- Boehringer Ingelheim
Small-Cell Lung Cancer
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage…
- Trial name
- IMforte (NCT05091567)
- Testing
- Atezolizumab, Lurbinectedin, Carboplatin
- Where
- 93 sites in United States, Belgium and 11 more
- Volunteers
- 660 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Disease, Diabetes
Improving Chronic Disease Management With Pieces
ICD-Pieces (Parkland Intelligent e-Coordination and Evaluation System) trial is a National Institutes of Health (NIH) Healthcare Systems(HCS) Collaboratory demonstration project to improve management of patients with a triad of…
- Conditions
- Chronic Kidney Disease, Diabetes, Hypertension, High BP
- Trial name
- ICD-Pieces (NCT02587936)
- Testing
- Collaborative Model of Primary care and Subspecialty care
- Where
- 4 sites in United States
- Volunteers
- 18,268 people
- Sponsor
- University of Texas Southwestern Medical Center
Chronic Thromboembolic Pulmonary Hypertension
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment
Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other…
- Trial name
- SELECT (NCT03689244)
- Testing
- Selexipag
- Where
- 162 sites in United States, Argentina and 29 more
- Volunteers
- 128 people
- Sponsor
- Actelion
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.